Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study
Background: The efficacy and effectiveness of nintedanib as a first-line therapy in idiopathic pulmonary fibrosis (IPF) patients have been demonstrated by clinical trials and real-life studies. Our aim was to examine the safety profile and effectiveness of nintedanib when it is utilized as a second-...
Main Authors: | Andrea Vianello, Francesco Salton, Beatrice Molena, Cristian Turato, Maria Laura Graziani, Fausto Braccioni, Valeria Frassani, Dino Sella, Paolo Pretto, Luciana Paladini, Andi Sukthi, Marco Confalonieri |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/2/422 |
Similar Items
-
Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
by: Gareth Hughes, et al.
Published: (2016-09-01) -
Pirfenidone vs nintedanib for treatment of idiopathic pulmonary fibrosis in clinical practice: efficacy, tolerability, and adverse effects
by: Amal A.E.-A Sadon, et al.
Published: (2020-01-01) -
Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report
by: Alessandro G. Fois, et al.
Published: (2020-10-01) -
Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly
by: Kuo-An Chu, et al.
Published: (2020-11-01) -
Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis
by: Mareike Lehmann, et al.
Published: (2018-09-01)